What is the approximate market price of a box of Isazomi?

As an anti-multiple myeloma targeted drug, Ixazomib belongs to the category of original high-end drugs, and its pricing is generally high globally. In China, the drug is marketed under the trade name of "Enleri" and is included in the scope of Class B drugs under the medical insurance. The common specifications are 4mg 1 tablet in 3 packs, 3mg 1 tablet in 3 packs and 2.5mg 1 tablet in 3 packs. Each box has a total of 3 pills, which are used for three times in one treatment cycle. Taking the 4mg specification as an example, after the adjustment of the medical insurance payment policy, the price of a box is about RMB 12,000-15,000, and the reimbursement ratio varies slightly due to different regional policies. Even so, the drug remains a high-cost treatment option for many families, and long-term use can cause significant financial stress.

Compared with domestic prices, ixazomib is more expensive in overseas markets. In the United States, according to statistics from the Drug Market Pricing Database, the price of original research Ixazomib can reach more than US$10,000 per box, which is why some patients try to find alternative purchasing methods. It is worth mentioning that in some countries, such as Laos and Bangladesh, original research manufacturers have set up factories or introduced equivalent drugs. The generic version or parallel imported drugs are also in 4mg*3 capsules, but the price is significantly lower, only about RMB 800-1,000 per box. This type of medicine is similar to the original medicine in terms of composition, bioavailability and consistency of efficacy.

Therefore, for patients who need to take ixazomib for a long time, it is recommended to give priority to formal purchase through medical insurance channels, and reasonably arrange the budget based on the medication cycle prescribed by the doctor. Some current drug assistance programs also provide price reductions or free medication services to patients with financial difficulties. In short, how to balance drug efficacy, safety and economic accessibility during maintenance treatment or long-term use of ixazomib is a practical problem currently faced by patients and doctors.

Reference materials:https://www.ninlaro.com/